Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

(This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

RSV, or Respiratory Syncytial Virus, is a highly contagious virus that frequently spreads among preschool children, ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

A mother’s worst nightmare is watching her child fall gravely ill, feeling helpless as the condition becomes worse. When ...